Temsirolimus: In Relapsed and/or Refractory Mantle Cell Lymphoma

ISSN： 0012-6667

Source： Drugs, Vol.70, Iss.14, 2010-10, pp. : 1819-1829

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3465-3471

Blackwell Publishing

Access to resources Recommend Favorite

Patients with relapsed or refractory mantle cell lymphoma may receive benefit from bortezomib

Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Preliminary Experience with Yttrium-90-labelled Rituximab (Chimeric Anti CD-20 Antibody) in Patients with Relapsed and Refractory B Cell Non-Hodgkins Lymphoma

Current Radiopharmaceuticals, Vol. 9, Iss. 2, 2016-08 ,pp. : 160-168

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma

By Prichard Mark Harris Thomas Williams Michael E Densmore John J

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 6, 2009-04 ,pp. : 983-995

Informa Healthcare

Access to resources Recommend Favorite

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 174-181

John Wiley & Sons Inc

Access to resources Recommend Favorite